

Asymchem Officially Launches New OEB5 Facility: Enabling Safe and Efficient Production of High-Potency Drugs

TIANJIN, CHINA, August 13, 2025 /EINPresswire.com/ -- Asymchem, a global leader in contract development and manufacturing solutions, has announced its [new OEB5 facility](#) is now officially operational. Designed for the highest international safety standards and equipped with advanced technologies, the facility significantly enhances large-scale HPAPI manufacturing capabilities.



Leading CDMO Company for Pharmaceutical Solutions

This 6,000 m², four-story plant is equipped with a full range of synthesis reactors (5 L to 1,000 L) and supporting isolation and purification systems, it enables end-to-end high-potency compounds from gram to multi-kilogram scale, with an annual capacity exceeding 500 kg. Each unit operation is supported by advanced engineering controls and automation systems, ensuring completely enclosed

“

The launch of our world-class HPAPI facility, built to meet the highest international standards, marks a significant milestone for Asymchem.”

Jianbo Yang, Head of HP

processes while significantly reducing manual handling. With a containment performance target (CPT) of 1 ng/m³, the facility fully meets the strict standards of safety and regulatory compliance.

The facility supports global HPAPI production, including payload-linkers, small molecules and more, meeting multi-phase demands from toxicology studies to commercial-scale production. Furthermore, with the HPAPI R&D lab launching in Q3 2025, Asymchem will establish a fully

integrated site that combines R&D, manufacturing, and analytical capabilities.

Jianbo Yang, Head of HP (High-Potency) Business Unit at Asymchem, commented, "The launch of our world-class HPAPI facility, built to meet the highest international standards, marks a significant milestone for Asymchem. We're now even better positioned to deliver safe, efficient,

and fully compliant solutions that help our global partners accelerate their path to market.” Asymchem will continue to deliver cGMP-compliant, safe, and efficient R&D and manufacturing services across the full drug lifecycle through leading technology and strict quality systems.

About Asymchem:

As a global CDMO leader, Asymchem (002821.SZ/6821.HK) offers end-to-end pharmaceutical solutions, excelling in small molecules, TIDES, biologics, drug products, synthetic biology, and more. With over 9,000 professionals and multiple facilities worldwide, we ensure cGMP compliance, cost efficiency, and client-centric services, empowering partners to accelerate drug development and commercialization.

For more information, please visit www.asymchem.com

Follow us on LinkedIn: www.linkedin.com/company/asymchem

Monica Wilson, Esq.

Asymchem, Inc.

[email us here](#)

Visit us on social media:

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/838967110>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.